Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of GL2702 GLARS-NF1 vs Omix Ocas in Healthy Males
NCT02072213Phase 1Completed
- Sponsor
- GL Pharm Tech Corp
- Start
- Aug 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tamsulosin in benign prostatic hyperplasia (BPH) (4 arms), sponsored by GL Pharm Tech Corp. Primary endpoints: Maximum Plasma Concentration at 48 hours and Area Under the Curve to Last Measurable Concentration at 48 hours. Started Aug 2013; status: completed.
02
Drugs
tamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT02072213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02072213.